Vogenx, Inc. (VOGX)
| Market Cap | 288.34M |
| Revenue (ttm) | n/a |
| Net Income | -1.65M |
| EPS | -0.30 |
| Shares Out | 14.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,186 |
| Open | 20.30 |
| Previous Close | 20.53 |
| Day's Range | 19.22 - 21.57 |
| 52-Week Range | 12.95 - 38.41 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 19, 2026 |
About VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Financial Performance
Financial StatementsNews
Vogenx initiates Phase 2b EMERGE study of mizagliflozin
Vogenx (VOGX) announced the initiation of EMERGE, its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycemia. There are currently no therapeutics approved by...
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery...
Vogenx appoints Gorman as Chief Commercial Officer
Vogenx (VOGX) announced that Richard Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026. Concurrent with his joining the management team, Gorman, who h...
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial read...
Vogenx appoints Ken Toombs to board of directors
Vogenx (VOGX) announced the appointment of Ken Toombs to its Board of Directors. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee. Toombs is…
Vogenx Appoints Ken Toombs to Board of Directors
Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company s...
Vogenx Quarterly report: Q2 2026
Vogenx has published its Q2 2026 quarterly earnings report on September 17, 2026.
Vogenx initiated with a Speculative Buy at WBB Securities
WBB Securities initiated coverage of Vogenx (VOGX) with a Speculative Buy rating and $42 price target The company’s mizagliflozin is an orally administered, minimally absorbed small molecule that sele...
Vogenx initiated with a Buy at Jones
Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with a Phase 2b-ready oral SGLT1 inhibitor in mizaglifloz...
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial publ...
Opening Day: Vogenx, Londian Wason debut strong on high end pricing
Vogenx and Londian Wason opened higher after upsized deals and high end pricing, underscoring still strong investor appetite for new listings. LATEST IPOS AND DIRECT LISTINGS: Vogenx (VOGX) opened on…
Vogenx 6.25M share IPO priced at $13.00
Vogenx (VOGX), a clinical-stage biopharmaceutical company focused on development of therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, priced its init...
Vogenx opens at $13, IPO priced at $13 per share
Vogenx (VOGX), a clinical-stage biopharmaceutical company focused on development of therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, priced its init...
Vogenx, Inc. trading halted, volatility trading pause
09:32 EDT Vogenx (VOGX), Inc. trading halted, volatility trading pause
Vogenx Announces Closing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for t...
Vogenx Announces Pricing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for t...
Vogenx Registration statement: Registration filing
Vogenx filed a registration statement on August 10, 2026, providing details about a securities offering with the SEC.
Vogenx Registration statement: Registration filing
Vogenx filed a registration statement on July 29, 2026, providing details about a securities offering with the SEC.
Vogenx IPO Registration Document (S-1)
Vogenx has filed to go public with an IPO on the NASDAQ
Metabolic disorders biotech Vogenx files for a US IPO
Vogenx, a Phase 2b biotech developing therapies for metabolic disorders, filed on Wednesday with the SEC to raise up to what we estimate could be $25 million in an initial public offering.